DrOlga Zubkova
Senior Scientist
Ferrier Research Institute
Orcid identifier0000-0002-6892-8812 (opens in a new tab)
- Senior ScientistFerrier Research Institute
- +6444630067 (Work)
- GIQ, Gracefield Innovation Quarter, Lower Hutt, Wellington, 5010, New Zealand
BIO
Dr Olga Zubkova has 30 years' experience as a carbohydrate and medicinal chemist. She joined Industrial Research Ltd (now the Ferrier Research Institute) in 1994 and has been involved in numerous research and commercial projects.
She is leading a programme “Novel heparanase inhibitors in multiple therapeutic applications” and has attracted significant funding to support her research.
Olga has been awarded grants from the New Zealand Federation of Women’s Institute to advance Alzheimer’s research (2016); $100,000 from the Breast Cancer Foundation New Zealand (2017) and $1,000,000 from the Ministry of Business, Innovation and Employment’s Endeavour Fund (2018) for her research.
Advanced (metastatic) breast cancer—for which there is currently no cure—is cancer that has spread beyond the breast to other organs in the body.
Dr Zubkova’s research targets a specific enzyme called heparanase. “Heparanase is a key influencer in the malignant behavior of cancers like breast cancer,” says Olga. “Heparanase weakens the elements that hold cells together and enables cancer cells to escape by breaking down tissue barriers. This means the primary tumour grows faster and spreads to remote parts of the body, becoming very difficult to treat.
“There are currently no therapeutically effective treatments that target heparanase available on the market.” Dr Zubkova plans to suppress heparanase using sugar-based compounds that she has developed over the past 15 years.
“These bio-inspired compounds have already been shown to significantly hinder the spread of blood and bone cancer in an animal model,” she says. “Our approach is to use the compounds to change the tumour’s environment in a cancer setting and restrict tumour growth, and ultimately the spread of cancer to other tissues, such as brain and liver.”
These compounds may be used in the treatment of colorectal, prostate, liver and brain cancers—and as maintenance therapies to help patients in remission to stay cancer-free. They are also proving effective for wound and bone healing, and for treatment of diabetes and neuroinflammatory diseases such as Alzheimers and Multiple Sclerosis.
Dr Zubkova’s programm is bringing together experts in medicinal chemistry, biochemistry and molecular biology from Victoria University of Wellington, the University of Otago and Auckland University in New Zealand, the Universities of Liverpool and Bristol (UK), A*STAR (Singapore), University of Sydney (Australia) and University of Alberta (Canada).
More information about Olga’s research is available at Wellington UniVentures.
She is leading a programme “Novel heparanase inhibitors in multiple therapeutic applications” and has attracted significant funding to support her research.
Olga has been awarded grants from the New Zealand Federation of Women’s Institute to advance Alzheimer’s research (2016); $100,000 from the Breast Cancer Foundation New Zealand (2017) and $1,000,000 from the Ministry of Business, Innovation and Employment’s Endeavour Fund (2018) for her research.
Advanced (metastatic) breast cancer—for which there is currently no cure—is cancer that has spread beyond the breast to other organs in the body.
Dr Zubkova’s research targets a specific enzyme called heparanase. “Heparanase is a key influencer in the malignant behavior of cancers like breast cancer,” says Olga. “Heparanase weakens the elements that hold cells together and enables cancer cells to escape by breaking down tissue barriers. This means the primary tumour grows faster and spreads to remote parts of the body, becoming very difficult to treat.
“There are currently no therapeutically effective treatments that target heparanase available on the market.” Dr Zubkova plans to suppress heparanase using sugar-based compounds that she has developed over the past 15 years.
“These bio-inspired compounds have already been shown to significantly hinder the spread of blood and bone cancer in an animal model,” she says. “Our approach is to use the compounds to change the tumour’s environment in a cancer setting and restrict tumour growth, and ultimately the spread of cancer to other tissues, such as brain and liver.”
These compounds may be used in the treatment of colorectal, prostate, liver and brain cancers—and as maintenance therapies to help patients in remission to stay cancer-free. They are also proving effective for wound and bone healing, and for treatment of diabetes and neuroinflammatory diseases such as Alzheimers and Multiple Sclerosis.
Dr Zubkova’s programm is bringing together experts in medicinal chemistry, biochemistry and molecular biology from Victoria University of Wellington, the University of Otago and Auckland University in New Zealand, the Universities of Liverpool and Bristol (UK), A*STAR (Singapore), University of Sydney (Australia) and University of Alberta (Canada).
More information about Olga’s research is available at Wellington UniVentures.
NON-ACADEMIC POSITIONS
- Senior ScientistThe Ferrier Research Institute, Carbohydrate Chemistry, Lower Hutt, New Zealand13 Jun 1994 - present
DEGREES
- PhD, ChemistryRostov State Medical University, Rostov-on-Don, Rostov-on-Don, Russia
LANGUAGES
- RussianCan read, write, speak, understand and peer review
AVAILABILITY
- Masters Research or PhD student supervision